Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMakker, Vicky
dc.contributor.authorTaylor, Matthew H.
dc.contributor.authorAghajanian, Carol
dc.contributor.authorOaknin benzaquen, Ana Mazaltob
dc.contributor.authorMier, James
dc.contributor.authorCohn, Allen L.
dc.date.accessioned2021-08-23T11:25:03Z
dc.date.available2021-08-23T11:25:03Z
dc.date.issued2020-09-10
dc.identifier.citationMakker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020 Sep 10;38(26):2981–2992.
dc.identifier.issn1527-7755
dc.identifier.urihttp://hdl.handle.net/11351/6231
dc.descriptionEndometrial Cancer; Lenvatinib
dc.description.abstractPURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors. METHODS Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORRWk24); secondary efficacy end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Tumor assessments were evaluated by investigators per immune-related RECIST. RESULTS At data cutoff, 108 patients with previously treated endometrial carcinoma were enrolled, with a median follow-up of 18.7 months. The ORRWk24 was 38.0% (95% CI, 28.8% to 47.8%). Among subgroups, the ORRWk24 (95% CI) was 63.6% (30.8% to 89.1%) in patients with microsatellite instability (MSI)–high tumors (n = 11) and 36.2% (26.5% to 46.7%) in patients with microsatellite-stable tumors (n = 94). For previously treated patients, regardless of tumor MSI status, the median DOR was 21.2 months (95% CI, 7.6 months to not estimable), median PFS was 7.4 months (95% CI, 5.3 to 8.7 months), and median OS was 16.7 months (15.0 months to not estimable). Grade 3 or 4 treatment-related adverse events occurred in 83/124 (66.9%) patients. CONCLUSION Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.
dc.language.isoeng
dc.publisherAmerican Society of Clinical Oncology
dc.relation.ispartofseriesJournal of Clinical Oncology;38(26)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEndometri - Càncer
dc.subjectMedicaments antineoplàstics - Ús terapèutic - Eficàcia
dc.subject.meshEndometrial Neoplasms
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.mesh/therapeutic use
dc.titleLenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1200/JCO.19.02627
dc.subject.decsneoplasias endometriales
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://ascopubs.org/doi/10.1200/JCO.19.02627
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Makker V, Aghajanian C] Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Taylor MH] Oregon Health & Science University, Portland, OR, USA. [Oaknin A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Mier J] Beth Israel Deaconess Medical Center, Boston, MA, USA. [Cohn AL] Rocky Mountain Cancer Center, Denver, CO, USA
dc.identifier.pmid32167863
dc.identifier.wos000574584300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record